Best Oncology Companies in Seongnam-si, South Korea
The 31 best Oncology companies in Seongnam-si, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Genexine.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Seongnam-si
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Genexine Developer of immunotherapeutics for treating orphan diseases, cancers & autoimmune disorders 40Product top 14%Patents top 25%Innovation top 32%Funding top 38% All 11 signals ▾Producttop 14% Patentstop 25% Innovationtop 32% Fundingtop 38% Talenttop 38% Moattop 41% Growthtop 45% Globalbottom 45% Marketbottom 37% Fin. healthbottom 34% Techbottom 23% Product: 10 distinct product lines · Company stage: Public Patents: 357 patents matched (strict assignee match) · 113 filings since 2022 vs 151 in 2017-21 rank vs industry peers · Fliar Intelligence Index 40/100 | $233M | 103 mo ago | Public | Young Sung Founder & Chairman | 2002 | NginxGoogle Font APIUnpkg+6 | 355 patents Biotech therapeutics: antibody fragments, cytokine fusion proteins, and cancer immunotherapy combos | — |
| 2 | ABL Bio Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases | $65M | 101 mo ago | Public | Sang Hoon Lee Ceo/Founder | 2016 | OpenSSLBootstrapApache HTTP Server+5 | 273 patents Bispecific antibody therapeutics targeting tumor antigens and immune co‑stimulatory receptors. | — |
| 3 | ImmuneOncia Developer of monoclonal and specific antibody for cancer treatment 11Funding top 37%Moat top 39%Market bottom 32%Global bottom 32% All 5 signals ▾Fundingtop 37% Moattop 39% Marketbottom 32% Globalbottom 32% Techbottom 23% Funding: Raised $60.5M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 11/100 | $60M | 57 mo ago | Public | — | 2016 | PHPGSAPApache HTTP Server+7 | — | — |
| 4 | Aprogen 🦄 Biotechnology company producing Biosimilars | $31M | 90 mo ago | Late Stage | — | 2000 | DreamWeaverJavaUNIX+10 | 63 patents Patents concentrated in chemistry & materials | — |
| 5 | 1ST Bio Developer of therapies for treating neurodegenerative and immuno-oncology diseases 53Funding top 28%Talent top 28%Market bottom 46%Global bottom 37% All 4 signals ▾Fundingtop 28% Talenttop 28% Marketbottom 46% Globalbottom 37% Funding: Raised $22.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 53/100 | $22M | 9 mo ago | Series D | — | 2016 | — | — | — |
| 6 | MediMabBio Developer of immunotherapeutics for treating cancer 29Moat top 32%Funding top 35%Talent top 38%Patents top 40% All 8 signals ▾Moattop 32% Fundingtop 35% Talenttop 38% Patentstop 40% Innovationtop 42% Globalbottom 31% Marketbottom 30% Techbottom 26% Moat: Editorial + unicorn rating 5/10 · IP moat: 28 patents Funding: Raised $17.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $18M | 12 mo ago | Series B | Hongseok Jo Co-Founder | 2017 | WordPressMySQLPHP+12 | 28 patents Immuno‑oncology: anti‑TIGIT/GITR antibodies and cytokine‑antibody fusion therapeutics | — |
| 7 | NOVOREX Developer of drugs for the treatment of cancer and central nervous diseases 32Funding top 33%AI top 45%Moat top 45%Patents top 50% All 8 signals ▾Fundingtop 33% AItop 45% Moattop 45% Patentstop 50% Talentbottom 45% Innovationbottom 38% Globalbottom 36% Marketbottom 34% Funding: Raised $15.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 32/100 | $15M | 6 mo ago | Series B | Woosung Son CEO | 2020 | — | 4 patents Small-molecule inhibitors targeting LRRK2 kinase and YEATS protein domains | — |
| 8 | Bertis Developer of AI-based diagnostic platform for cancer and cardiac diseases | $13M | 65 mo ago | Series B | Inhoi Koo Co-Founder | 2014 | GnuboardMySQLPHP+15 | 81 patents Clinical diagnostics using mass spectrometry and biomarker-based cancer detection assays | — |
| 9 | Bridge Biotherapeutics Developer of small molecule based therapeutics for the treatment of various diseases | $10M | 112 mo ago | Acquired | James Jungkue Lee Founder & CEO | 2015 | PHPNginxCloudflare+10 | 36 patents Small-molecule enzyme inhibitors and PROTACs for calcification and targeted protein degradation | — |
| 10 | Novelty Nobility Developer of therapeutics for eye and cancer diseases | $8M | 81 mo ago | Series A | Sang Park Founder & CEO | 2018 | — | 55 patents Therapeutic antibodies and ADCs targeting c-Kit, CDCP1, HIF‑1α for oncology and mast cell disorders | — |
| 11 | Genome & Company Developer of microbiome-based immuno-oncology drugs | $3M | 78 mo ago | Public | Jisoo Pae Co-Founder & CEO | 2015 | — | 252 patents Microbial strains for cancer therapy/diagnostics and BCAM-targeted antibody‑drug conjugates | — |
Top 12 Oncology companies in Seongnam-si
#1
Series B · Seongnam-si, Gyeonggi-do · founded 2020 · 20 employees$15Mraised▾
Developer of drugs for the treatment of cancer and central nervous diseases. The company develops GPCR-targeted small-molecule drugs using artificial intelligence to treat neurological disorders, cognitive function, and cancer.
- Apr 2026Series B$15M
#2
Series D · Seongnam-si, Gyeonggi-do · founded 2016 · 34 employees$22Mraised▾
1ST Bio is developing therapies for treating neurodegenerative and immuno-oncological diseases. The lead candidate of the company, 1ST 102 is a tyrosine kinase enzyme inhibitor. It's in the preclinical phase which is used for treating Parkinson's Disease. Other candidates like 1ST-101 and 1ST-103 are in the discovery stage.
- Jan 2026Series D$22M
#3
Series B · Seongnam-si, Gyeonggi-do · founded 2017 · 19 employees$17.8Mraised▾
MediMabBio is a developer of immunotherapeutics for treating cancer. The company develops immuno-oncology drugs using its drug discovery platform with a combination of systems biology and immunological solutions to target solid tumors. The products pipeline includes immune checkpoint antibody (MMB-101) in lead optimization stage and immuno cytokine agents (MMB-201) in hit optimization stage.
- Oct 2025Series B$17.8M
#4
Public · Seongnam-si, Gyeonggi-do · founded 2002$233Mraised▾
Developer of immunotherapeutics for treating orphan diseases, cancers & autoimmune disorders. The company has developed drug candidates for Growth Hormone Deficiencies, Cervical Cancers, and Anemias. Its technology is based on Fc fusion proteins and DNA Vaccines.
- Mar 2018Post IPO$233M
#5
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 21 employees$60.5Mraised▾
Developer of monoclonal and specific antibody for cancer treatment. The company's lead antibody IMC-001 is currently in phase 1 of the clinical trial. The company has a pipeline of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.
- Jan 2022Series B$20.5M
- Feb 2019Series A$40M
#6
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 93 employees$65Mraised▾
ABL Bio is a Korean, clinical-stage biopharma developing immunotherapies for oncology and neurodegenerative diseases. Their first lead candidate is ABL001 a bispecific antibody targeting DII4 & VEGF and is indicated for solid tumors. The second bispecific antibody is ABL301, a BBB penetrating Bispecific antibody for targeting Alpha-Synuclein, and indicated for Parkinson's Disease and other synucleopathies. The company is developing 4 ADCs for various cancer indications (MM, AML, CLL, TNBC).
- Jun 2018Series C$65M
- 2016Seed—
#7
Aprogen 🦄Late Stage · Seongnam-si, Gyeonggi-do · founded 2000 · 66 employees$30.7Mraised▾
Aprogen is a Korean Biotech that develops its own biologics and also biosimilars. It is developing biosimilar products for various biologics including infliximab, trastuzumab, adalimumab, and bevacizumab. In terms of novel biologics, it is developing AP185, AP216, and other new candidates targeted for vascular disease and oncology market. Currently, Aprogen can manufacture over 80 kg of APIs of biopharmaceuticals annually and it has undertaken construction of the second factory with annual manufacturing capacity over 2,000 kg of API and a fill-finish facility, which is expected to be completed by the end of 2017. The first lead candidate, AP185, is a fusion protein of the functional C-terminal domain of angiopoietin 1 (Ang1) and short coiled-coil domain of cartilage oligomeric matrix protein (COMP). AP185 indicated for damaged blood vessels caused by myocardial infarction, diabetic foot ulcer, and erectile dysfunction. The second lead candidate, AP216, is a fusion protein of angiopoietin binding domain of TIE2, Ig2 domain of VEGFR, and Fc domain of immunoglobulin G1. AP216 blocks angiogenic action in various cancers, such as ovarian and lung cancers, by effective suppression of
- May 2019PE$16.7M
- Jul 2012PE$14M
#8
Series B · Seongnam-si, Gyeonggi-do · founded 2014 · 46 employees$13.5Mraised▾
Developer of AI-based diagnostic platform for cancer and cardiac diseases. The company's lead product MASTOCHECK is a proteomics-based blood test to detect breast cancer. Another product is a cardiovascular disease marker which is a non-invasive blood test that detects the biomarkers present in the blood.
- Jun 2021Series B$13.5M
#9
Series A · Seongnam-si, Gyeonggi-do · founded 2018 · 33 employees$8.4Mraised▾
Novelty nobility is developing the therapeutics for eye and cancer diseases. The company has ongoing clinical trials on NN3201, NN3901, and NN2901 for ophthalmology and eye disease indications. The company uses technology as the SCF/c-KIT pathway as a drug target.
- Feb 2020Series A$8.4M
#10
Acquired · Seongnam-si, Gyeonggi-do · founded 2015 · 6 employees$10Mraised▾
Bridge Biotherapeutics is developing small molecule-based therapeutics for the treatment of various diseases such as ulcerative colitis, fibrotic diseases, and cancers. The company's product pipeline which includes BBT-401, a pellino-1 inhibitor used against ulcerative colitis is in Phase 2 clinical trials, BBT-877, an autotaxin inhibitor used against idiopathic pulmonary fibrosis is in Phase 2 clinical trials. Other products of the company are in the development stage.
- Jul 2017Series A$10M
- 2015Seed—
#11
Public · Seongnam-si, Gyeonggi-do · founded 2015 · 108 employees$3Mraised▾
Developer of microbiome-based immuno-oncology drugs. The company is developing innovative microbiome and novel target-based drug candidates based on a proprietary GNOCLE technology platform. The company's pipeline includes GEN-001, SB-121, and GEN-004 for cancer, autism, and obstetric diseases
- Apr 2020Post IPO$3M
- 2016Seed—
#12
Seed · Seongnam-si, Gyeonggi-do · founded 2022—raised▾
Developer of immunotherapies for the treatment of cancer. The company is focused on developing anti-tumor therapeutics for the treatment of cancer by regulating the TME.
- Feb 2024Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in South Korea
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,493 South Korea-affiliated papers.
- Ministry of Education247
- Seoul National University134
- National Cancer Center127
- Sungkyunkwan University117
- Yonsei University105
- Tumor microenvironment8→257
- Immune system2→205
- Cancer research6→178
- Cancer cell1→37
- Immune checkpoint1→28
- Tumor microenvironment5→371
- Immune system4→262
- Cancer research8→246
- Immunotherapy2→234
- Cancer immunotherapy3→104
- Immune system1→49
- Cancer cell1→4
- Metastasis1→4
Where oncology is researched across South Korea
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing oncology patents in South Korea
South Korea oncology patent filing is accelerating — 367 filings from 129 assignees (2016–2025), led by Korea Advanced INST SCI & TECH, UNIV Yonsei IACF, UNIV Ulsan Found IND COOP; annual filings 4→73.
- Korea Advanced INST SCI & TECH27
- UNIV Yonsei IACF23
- UNIV Ulsan Found IND COOP19
- ASAN Found18
- Seoul NAT UNIV R&DB Foundation18
- GI Innovation17
- Genemedicine16
- Samsung15
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.